MedPacto Reveals Data on Bactosertib Combination at ESMO... "Survival Period Increased by 10 Months"

MedPacto announced on the 23rd that it presented clinical data on the combination therapy of Betosertib for metastatic colorectal cancer at the 'European Society for Medical Oncology Annual Meeting 2023 (ESMO 2023)'.

MedPacto announced on the 23rd that it presented clinical data on the combination therapy of Betosertib for metastatic colorectal cancer in a poster session at the European Society for Medical Oncology Annual Meeting 2023 (ESMO 2023). On-site photo at ESMO.
[Photo by MedPacto]

The data disclosed this time is clinical data on the combination therapy of Betosertib (200 mg and 300 mg) and Keytruda (pembrolizumab) in 105 patients with metastatic colorectal cancer who failed previous treatments, observing safety and efficacy after combined administration. Notably, at this ESMO, clinical data for patients treated with Betosertib 300 mg in combination was officially disclosed for the first time. Previously, MedPacto had revealed data on Betosertib 200 mg combination therapy at the 2021 American Society of Clinical Oncology (ASCO) meeting.

According to the presentation, the median overall survival (mOS) of the patient group treated with Betosertib 300 mg combined with Keytruda was 17.35 months, and the objective response rate (ORR) was 18.75%. Additionally, the mOS for the Betosertib-treated patient group, including those receiving 300 mg, was 15.8 months. The ORR for the entire patient group was 13.33%.

MedPacto explained that the mOS figure of Betosertib 300 mg is more than 10 months higher compared to the mOS of currently used standard treatments such as Regorafenib (6.4 months) and Trifluridine/Tipiracil (7.1 months). It is also nearly 7 months longer than the overall survival (OS) of 10.8 months reported in the recently published Trifluridine/Tipiracil plus Bevacizumab combination therapy (Sunlight study).

The ORR of Betosertib 300 mg also showed superiority compared to existing standard treatments Regorafenib (1.0%) and Lonsurf (1.6%). Furthermore, MedPacto explained that only manageable side effects occurred in some colorectal cancer patients treated with Betosertib combination therapy, and no fatal side effects were confirmed, demonstrating safety.

Based on this clinical data, MedPacto plans to submit a follow-up clinical trial plan (IND) for metastatic colorectal cancer patients to the U.S. Food and Drug Administration (FDA) within this year.

A MedPacto official stated, "It has been confirmed that the combination therapy of Betosertib and Keytruda in metastatic colorectal cancer patients shows significantly superior therapeutic effects compared to standard treatments. In particular, the median overall survival (mOS) of the Betosertib 300 mg treatment group is more than 10 months longer than that of standard treatments," adding, "We will also accelerate global follow-up clinical trials for metastatic colorectal cancer patients based on the data disclosed this time."

Meanwhile, ESMO is one of the three major cancer societies along with the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). Every year, experts worldwide, global big pharma, and industry stakeholders participate to share key research and development (R&D) achievements.

This content was produced with the assistance of AI translation services.